Aldevron

09/03/2026

We're looking forward to joining the RNA Vaccines & Therapeutics Conference in London, where leaders from across academia, biotech, and pharma will come together to explore the innovations shaping the future of RNA medicines. Discussions will span RNA design, delivery, manufacturing, scale-up, and the collaborative pathways needed to move promising therapies from concept to clinic.

Our very own Christian Boada will also be presenting his scientific poster: "mRNA Drug Substance Journey to LNP Drug Product: Scale-Up Via Microfluidic Mixing."

If you're attending, we'd love to connect and discuss how scalable manufacturing strategies can help advance the next generation of RNA vaccines and therapeutics.

09/02/2026

How confident are you in your viral vector CMC strategy?

Early CMC decisions can have a lasting impact on development timelines, manufacturing scalability, regulatory readiness, and long-term program flexibility.

That's why we've created a practical CMC Planning Checklist for Viral Vector Programs to help teams evaluate key considerations before timelines and processes become more fixed.

The checklist covers:
✅ Development strategy alignment with future clinical goals
✅ Plasmid design and quality considerations
✅ Manufacturing and scale readiness
✅ Regulatory and documentation expectations

Download the checklist and assess your program's readiness for the next stage of development: https://ald.bio/4dh45v5

09/01/2026

Lead optimization moves quickly. Your RNA supplier should too.

Whether you're screening multiple constructs, evaluating doses, or advancing promising candidates, Aldevron's online store makes it easy to order the research grade mRNA you need, when you need it.

Key benefits include:
• Instant pricing with no sales process
• Flexible quantities sized for your research stage
• Faster turnaround enabled by cell-free DNA template production
• Research grade material backed by extensive clinical manufacturing experience

And when your program progresses? You're already working with a manufacturer trusted to support RNA programs from discovery through commercialization.

Spend less time sourcing materials and more time generating data. Order now: https://ald.bio/4g89i9h

What would make ordering RNA materials easier for your team?

09/01/2026

During National Sickle Cell Awareness Month, we recognize the patients, families, caregivers, advocates, clinicians, and researchers working to advance understanding of sickle cell disease and improve the future of care.

Last year, Aldevron welcomed Victoria Gray, the first person to have their cells edited using CRISPR for sickle cell disease, as part of our Advance Beyond symposium. Her story was a powerful reminder that scientific progress is ultimately measured by its impact on people and families.

Victoria spoke about the realities of living with sickle cell disease, the hope that research can create, and the importance of continuing to expand access for patients who need it most.

This month, we honor the resilience of the sickle cell community and the individuals whose experiences continue to inspire the pursuit of new discoveries and new possibilities.

08/28/2026

Scientific progress depends on more than technical expertise. It depends on environments where people can do their best work safely and confidently.

On World Day for Safety and Health at Work, we celebrate the teams whose commitment to safety, quality, and operational excellence helps make innovation possible.

Because when safety is embedded in every step, better outcomes follow.

08/27/2026

How early is too early to start thinking about manufacturing?

For gene-modified cell therapies, choices made during plasmid design can create advantages or challenges that persist all the way through commercialization.

That's why it's critical to align vector design, critical materials, and cGMP manufacturing strategies from the beginning.

Join us on September 8 to learn how organizations can improve continuity across development stages while supporting more reproducible and scalable outcomes.
Discover:

• The downstream impact of plasmid design decisions
• Ways to reduce process variability
• Strategies for scaling with confidence
• How to bridge common gaps between development and manufacturing teams

September 8, 2026 | 10:30 AM EDT / 4:30 PM CEST

Save your spot: https://ald.bio/4goRurC

08/26/2026

Plasmid DNA remains foundational to gene editing, but the vector design you choose can have a significant impact on expression, cell health, and scalability. Next-generation Nanoplasmid™ vectors were developed to address challenges associated with conventional plasmids through a minimal, antibiotic-free backbone designed to support stronger expression, improved cell viability, and gene editing performance.

In our latest blog, explore how Nanoplasmid™ DNA is helping researchers advance scalable gene editing workflows and why plasmid design remains an important consideration as programs move from discovery toward clinical development.

Read the blog now: https://ald.bio/4qM6fso

Learn how Nanoplasmid DNA supports scalable gene editing with cleaner payloads, improved expression, and GMP-compatible production.

08/18/2026

Your RNA workflow just got a lot simpler.

For many research teams, ordering materials can create unnecessary delays. Waiting for quotes, exchanging emails to confirm specifications, and navigating procurement processes all add time before work can begin.

Research grade mRNA is now available through Aldevron's online store, giving scientists more control over how they source RNA for their programs. Configure important specifications such as capping method, quantity, and endotoxin requirements, then place your order when it works for your timeline.

Behind every order is a partner trusted for high-quality mRNA manufacturing since 2017, with the expertise to support programs from discovery through commercialization.

The same quality you count on. Ordering that finally keeps pace with your research.

Ready to get started? Explore research grade mRNA from Aldevron: https://ald.bio/4cAEhts

08/13/2026

In gene-modified cell therapy, manufacturing success starts long before cGMP production.

Decisions made during plasmid design can influence reproducibility, scalability, and overall program efficiency throughout development. Yet many organizations still approach vector design, critical materials, and manufacturing as separate activities.

Join us on September 8 as industry experts discuss practical strategies for building a more connected workflow from early development through commercialization.

Key discussion topics:
✅ How plasmid design impacts downstream performance
✅ Approaches to improve consistency and reduce variability
✅ Considerations for scaling manufacturing processes
✅ Common points of disconnect and how to address them

September 8, 2026 | 10:30 AM EDT / 4:30 PM CEST

Register today: https://ald.bio/4fPSqFx

As gene-modified cell therapy programs move into later-stage development, maintaining continuity across plasmid design and manufacturing becomes increasingly critical. Challenges at Phase II

08/12/2026

How do you accelerate RNA capping process development without sacrificing analytical confidence?

As mRNA-based vaccines and therapeutics advance, development teams need analytical workflows that can evaluate more samples, compare process conditions efficiently, and support faster decision-making.

In this presentation, Rebecca Young explores how combining InDevR's VaxArray® 5'CapQ assay with HPLC-based methods can help streamline RNA capping process development. The approach pairs high-throughput analysis with detailed confirmation, providing valuable insight into capping efficiency and RNA integrity from early R&D through manufacturing readiness.

Read the presentation highlights: https://ald.bio/45WtjLe

VaxArray 5’CapQ and HPLC-based methods streamline RNA capping analysis for faster, data-driven mRNA process development workflows.